SG10201605152SA - Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors - Google Patents
Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitorsInfo
- Publication number
- SG10201605152SA SG10201605152SA SG10201605152SA SG10201605152SA SG10201605152SA SG 10201605152S A SG10201605152S A SG 10201605152SA SG 10201605152S A SG10201605152S A SG 10201605152SA SG 10201605152S A SG10201605152S A SG 10201605152SA SG 10201605152S A SG10201605152S A SG 10201605152SA
- Authority
- SG
- Singapore
- Prior art keywords
- alpha
- acid derivatives
- boronic acid
- amino boronic
- immunoproteasome inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579076P | 2011-12-22 | 2011-12-22 | |
| EP11195107 | 2011-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201605152SA true SG10201605152SA (en) | 2016-08-30 |
Family
ID=48667763
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201605152SA SG10201605152SA (en) | 2011-12-22 | 2012-12-21 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| SG11201403254QA SG11201403254QA (en) | 2011-12-22 | 2012-12-21 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201403254QA SG11201403254QA (en) | 2011-12-22 | 2012-12-21 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9688702B2 (OSRAM) |
| EP (1) | EP2793900B1 (OSRAM) |
| JP (1) | JP6129203B2 (OSRAM) |
| KR (1) | KR20140114391A (OSRAM) |
| CN (1) | CN104321060B (OSRAM) |
| AU (1) | AU2012356890B2 (OSRAM) |
| BR (1) | BR112014015363A2 (OSRAM) |
| CA (1) | CA2860142C (OSRAM) |
| EA (1) | EA201400735A1 (OSRAM) |
| ES (1) | ES2699267T3 (OSRAM) |
| HK (1) | HK1206261A1 (OSRAM) |
| IL (1) | IL233200A (OSRAM) |
| MX (1) | MX352652B (OSRAM) |
| SG (2) | SG10201605152SA (OSRAM) |
| WO (1) | WO2013092979A1 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE048859T2 (hu) | 2010-08-10 | 2020-08-28 | Rempex Pharmaceuticals Inc | Gyûrûs bórsavészter származékok, eljárás elõállításukra, és terápiás alkalmazásuk |
| WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| ES2615744T3 (es) * | 2012-12-03 | 2017-06-08 | F. Hoffmann-La Roche Ag | Compuestos de ácido triazol-borónico sustituidos |
| KR102147420B1 (ko) | 2012-12-07 | 2020-08-25 | 베나토알엑스 파마슈티컬스, 인크. | 베타-락타마제 억제제 |
| CA2894891A1 (en) * | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| BR112015016002A2 (pt) * | 2013-01-04 | 2017-07-11 | Rempex Pharmaceuticals Inc | compostos, composições farmacêuticas, complexos químicos e respectivos usos e método para tratar ou prevenir infecção bacteriana |
| US9403850B2 (en) | 2013-01-10 | 2016-08-02 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2014151958A1 (en) | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| ES2748434T3 (es) | 2014-01-10 | 2020-03-16 | Univ Cornell | Dipéptidos como inhibidores de inmunoproteasomas humanos |
| ES2750805T3 (es) | 2014-05-05 | 2020-03-27 | Rempex Pharmaceuticals Inc | Síntesis de sales de boronato y usos de las mismas |
| WO2015171398A1 (en) | 2014-05-05 | 2015-11-12 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| EA201691988A1 (ru) | 2014-05-19 | 2017-06-30 | Ремпекс Фармасьютикалз, Инк. | Производные бороновой кислоты и их терапевтическое применение |
| PL3154989T3 (pl) * | 2014-06-11 | 2021-10-18 | VenatoRx Pharmaceuticals, Inc. | Inhibitory beta-laktamaz |
| US10206937B2 (en) | 2014-07-01 | 2019-02-19 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US11202817B2 (en) | 2014-08-18 | 2021-12-21 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
| CA2963186A1 (en) * | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| RU2017115188A (ru) * | 2014-10-01 | 2018-11-06 | Мерк Патент Гмбх | Производные бороновой кислоты |
| ES2761774T3 (es) * | 2014-10-01 | 2020-05-21 | Merck Patent Gmbh | Derivados del ácido borónico |
| WO2016050356A1 (en) | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP3347008B1 (en) | 2015-09-11 | 2022-03-09 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| CN114306297A (zh) | 2015-10-15 | 2022-04-12 | 康奈尔大学 | 蛋白酶体抑制剂及其用途 |
| WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| CN107151255A (zh) * | 2016-03-06 | 2017-09-12 | 复旦大学 | 硼酸类化合物及其制备方法和用途 |
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| CN110959008A (zh) | 2017-05-26 | 2020-04-03 | 维纳拓尔斯制药公司 | 青霉素结合蛋白抑制剂 |
| WO2018218154A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| PT3672977T (pt) | 2017-08-24 | 2022-09-23 | Merck Patent Gmbh | Derivados do ácido borónico |
| BR112020007138B1 (pt) | 2017-10-11 | 2023-03-21 | Qpex Biopharma, Inc | Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos |
| US11203613B2 (en) | 2017-10-11 | 2021-12-21 | Cornell University | Peptidomimetic proteasome inhibitors |
| CN107556336A (zh) * | 2017-10-16 | 2018-01-09 | 康化（上海）新药研发有限公司 | 一种呋喃‑2‑甲烷基硼酸频哪醇酯的合成方法 |
| EP3710458A1 (en) | 2017-11-16 | 2020-09-23 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| RS63666B1 (sr) | 2017-11-16 | 2022-11-30 | Principia Biopharma Inc | Inhibitori imunoproteazoma |
| CN108130370B (zh) * | 2018-01-05 | 2020-11-17 | 武汉惠康达科技有限公司 | Psmb8及其抑制剂在制备治疗脂肪肝及其相关疾病药物中的应用 |
| EP3781576B1 (en) | 2018-04-20 | 2024-06-12 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN112469725A (zh) | 2018-05-25 | 2021-03-09 | 维纳拓尔斯制药公司 | 青霉素结合蛋白抑制剂 |
| IL280376B2 (en) | 2018-07-26 | 2024-08-01 | Merck Patent Gmbh | Boronic acid derivatives, their preparation and pharmaceutical compositions containing them |
| CN113135944A (zh) * | 2020-01-19 | 2021-07-20 | 首药控股(北京)有限公司 | 硼酸衍生物 |
| CN114075227B (zh) | 2020-08-19 | 2023-07-04 | 北京嵩润医药科技有限责任公司 | 吡唑硼酸类化合物、包含其的药物组合物及它们的用途 |
| EP4301466A4 (en) * | 2021-03-02 | 2025-08-20 | Univ Case Western Reserve | BETA-LACTAMASE INHIBITORS AND THEIR USES |
| JP7758028B2 (ja) * | 2021-03-05 | 2025-10-22 | Ａｇｃ株式会社 | 化合物、化合物の製造方法及び表面処理剤の製造方法 |
| EP4377324A1 (en) | 2021-07-29 | 2024-06-05 | Merck Patent GmbH | Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain |
| JP7734276B2 (ja) * | 2021-10-14 | 2025-09-04 | ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド | ボロン酸誘導体 |
| WO2023232830A1 (en) | 2022-06-02 | 2023-12-07 | Merck Patent Gmbh | Boronic acid adducts |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111175A0 (en) * | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
| US7332343B2 (en) | 2004-01-16 | 2008-02-19 | Board Of Regents, The University Of Texas System | Determining enantiomeric excess using indicator-displacement assays |
| LT3385267T (lt) * | 2004-03-30 | 2021-11-10 | Millennium Pharmaceuticals, Inc. | Borono rūgšties esterio ir rūgšties junginių sintezė |
| JP5232160B2 (ja) | 2006-11-14 | 2013-07-10 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしての三環式芳香族複素環化合物 |
| EP2527347A1 (en) * | 2007-08-06 | 2012-11-28 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| JP5600595B2 (ja) * | 2007-10-16 | 2014-10-01 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | プロテアソーム阻害剤 |
| KR20100109901A (ko) * | 2007-11-13 | 2010-10-11 | 프로테즈 파마슈티칼스, 인크. | 베타-락타마제 억제제 |
| AR075090A1 (es) * | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| CA2794334C (en) * | 2010-03-31 | 2018-06-12 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| WO2011137049A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Heterocyclic quinolizine derived m1 receptor positive allosteric modulators |
-
2012
- 2012-12-21 CA CA2860142A patent/CA2860142C/en active Active
- 2012-12-21 HK HK15106906.3A patent/HK1206261A1/xx unknown
- 2012-12-21 ES ES12806491T patent/ES2699267T3/es active Active
- 2012-12-21 MX MX2014007362A patent/MX352652B/es active IP Right Grant
- 2012-12-21 EA EA201400735A patent/EA201400735A1/ru unknown
- 2012-12-21 SG SG10201605152SA patent/SG10201605152SA/en unknown
- 2012-12-21 KR KR1020147020413A patent/KR20140114391A/ko not_active Ceased
- 2012-12-21 CN CN201280063440.0A patent/CN104321060B/zh not_active Expired - Fee Related
- 2012-12-21 WO PCT/EP2012/076595 patent/WO2013092979A1/en not_active Ceased
- 2012-12-21 JP JP2014548061A patent/JP6129203B2/ja not_active Expired - Fee Related
- 2012-12-21 SG SG11201403254QA patent/SG11201403254QA/en unknown
- 2012-12-21 BR BR112014015363A patent/BR112014015363A2/pt not_active Application Discontinuation
- 2012-12-21 US US14/366,949 patent/US9688702B2/en not_active Expired - Fee Related
- 2012-12-21 AU AU2012356890A patent/AU2012356890B2/en not_active Ceased
- 2012-12-21 EP EP12806491.2A patent/EP2793900B1/en active Active
-
2014
- 2014-06-17 IL IL233200A patent/IL233200A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN104321060A (zh) | 2015-01-28 |
| JP6129203B2 (ja) | 2017-05-17 |
| BR112014015363A8 (pt) | 2017-06-13 |
| EA201400735A1 (ru) | 2015-04-30 |
| IL233200A0 (en) | 2014-07-31 |
| WO2013092979A1 (en) | 2013-06-27 |
| US20140364396A1 (en) | 2014-12-11 |
| HK1206261A1 (en) | 2016-01-08 |
| EP2793900A1 (en) | 2014-10-29 |
| AU2012356890B2 (en) | 2017-06-08 |
| IL233200A (en) | 2017-08-31 |
| ES2699267T3 (es) | 2019-02-08 |
| MX352652B (es) | 2017-12-04 |
| MX2014007362A (es) | 2014-08-01 |
| CA2860142C (en) | 2020-10-27 |
| CN104321060B (zh) | 2018-08-07 |
| EP2793900B1 (en) | 2018-08-22 |
| US9688702B2 (en) | 2017-06-27 |
| JP2015502387A (ja) | 2015-01-22 |
| AU2012356890A1 (en) | 2014-08-07 |
| BR112014015363A2 (pt) | 2017-06-13 |
| KR20140114391A (ko) | 2014-09-26 |
| SG11201403254QA (en) | 2014-07-30 |
| CA2860142A1 (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201605152SA (en) | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | |
| ZA201305826B (en) | Substituted amminobutyric derivatives as neprilysin inhibitors | |
| ZA201305612B (en) | Pyrrolotriazinone derivatives as pi3k inhibitors | |
| ZA201401884B (en) | New dihydroquinoline-2-one derivatives | |
| SG10201601802YA (en) | Dispiropyrrolidine derivatives | |
| PL3415616T3 (pl) | Sposób odmładzania komórek | |
| IL228949A0 (en) | History of pyrazolospiroctone for use as acetyl-CoA carboxylase inhibitors | |
| PL2721039T3 (pl) | Chelatowane inhibitory PSMA | |
| IL235425B (en) | History of lysine-glutamic acid di-peptide | |
| EP2782580A4 (en) | SELECTIVE INHIBITORS OF KINASES | |
| SG11201401937YA (en) | New aryl-quinoline derivatives | |
| ZA201307496B (en) | Novel rock inhibitors | |
| GB201304499D0 (en) | Carcainium Salts | |
| IL247640A0 (en) | History of heteroaryl piperidine | |
| IL233712A0 (en) | Sulfonamide derivatives used as mogat–2 inhibitors | |
| GB2503122B (en) | Running tool | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| EP2744788A4 (en) | BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS | |
| GB201114854D0 (en) | Novel rock inhibitors | |
| SI2766342T1 (sl) | Derivati fenil-gvanidina | |
| ZA201308049B (en) | 3-ureidoisoquinolin-8-yl derivatives | |
| ZA201405367B (en) | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | |
| GB201120474D0 (en) | Inhibitors | |
| GB201104399D0 (en) | Novel inhibitors | |
| ZA201209319B (en) | Cyclopropyl-indole derivatives |